Cargando…

Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months

SARS-CoV-2 vaccines have shown very high effectiveness in real-world scenarios. However, there is compelling evidence for a fast-paced waning of immunity. The increasing number of new variants that could alter the severity, transmissibility, and potential to evade the immune response raised signific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopera, Tulio J., Chvatal-Medina, Mateo, Flórez-Álvarez, Lizdany, Zapata-Cardona, Maria I., Taborda, Natalia A., Rugeles, Maria T., Hernandez, Juan C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108166/ https://www.ncbi.nlm.nih.gov/pubmed/35585980 http://dx.doi.org/10.3389/fimmu.2022.879036

Ejemplares similares

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach
por: Zapata-Cardona, Maria I., et al.
Publicado: (2023)

Dynamics of humoral immune response in SARS-CoV-2 infected individuals with different clinical stages
por: Mendez-Cortina, Yorjagis, et al.
Publicado: (2022)

Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients
por: Agur, Timna, et al.
Publicado: (2022)

NK cells from Men Who Have Sex with Men at high risk for HIV-1 infection exhibit higher effector capacity
por: Rincón, Daniel S., et al.
Publicado: (2023)

Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms
por: Marín-Palma, Damariz, et al.
Publicado: (2021)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
por: Altieri, Manuela, et al.
Publicado: (2022)

The Hydroalcoholic Extract of Uncaria tomentosa (Cat's Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Vitro
por: Yepes-Perez, Andres F., et al.
Publicado: (2021)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

Atorvastatin Effectively Inhibits Ancestral and Two Emerging Variants of SARS-CoV-2 in vitro
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

Humoral and Cellular Response and Associated Variables Nine Months following BNT162b2 Vaccination in Healthcare Workers
por: Syrimi, Natalia, et al.
Publicado: (2023)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant
por: Peled, Yael, et al.
Publicado: (2022)

Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2021)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Aspects of Humoral Immunity after Vaccination with Bnt162b2: A Small Study
por: GIUBELAN, LUCIAN-ION, et al.
Publicado: (2022)

Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases
por: Leung, Daniel, et al.
Publicado: (2023)

Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, following Vaccination with BNT162b2
por: Fylaktou, Asimina, et al.
Publicado: (2023)

Comparison among plaque assay, tissue culture infectious dose (TCID(50)) and real-time RT-PCR for SARS-CoV-2 variants quantification
por: Zapata-Cardona, Maria Isabel, et al.
Publicado: (2022)

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
por: Mavrovouniotis, Ilias, et al.
Publicado: (2023)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours
por: Margalit, Ofer, et al.
Publicado: (2022)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - Implications for the omicron variant: Correspondence
por: Peled, Yael, et al.
Publicado: (2022)

Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine
por: Uwamino, Yoshifumi, et al.
Publicado: (2023)

Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
por: Melin, Jan, et al.
Publicado: (2021)

Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2022)

Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2022)

Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis
por: Dekervel, Marine, et al.
Publicado: (2021)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2
por: Vollenberg, Richard, et al.
Publicado: (2022)

Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients
por: De Cagna, Maria Rosaria, et al.
Publicado: (2023)

Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine
por: Gandolfo, Claudia, et al.
Publicado: (2022)

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
por: Naaber, Paul, et al.
Publicado: (2021)

Antibody Responses in COVID-19: A Review
por: Chvatal-Medina, Mateo, et al.
Publicado: (2021)

Six-Month Follow-Up after Vaccination with BNT162b2: SARS-CoV-2 Antigen-Specific Cellular and Humoral Immune Responses in Hemodialysis Patients and Kidney Transplant Recipients
por: Boedecker-Lips, Simone Cosima, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ereem9eq616okn9ohr74r3u8n6